Sara Bettonte

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Ideal Time to Conduct a Pharmacokinetic Investigation After Delivery to Fully Capture the Effect of Pregnancy on Drug Exposure.

Ideal Time to Conduct a Pharmacokinetic Investigation After Delivery to Fully Capture the Effect of Pregnancy on Drug Exposure.

Journal: Open forum infectious diseases

Published: May 28, 2024

Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study.

Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study.

Journal: Open forum infectious diseases

Published: December 30, 2023

Development of a physiologically-based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs.

Development of a physiologically-based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs.

Journal: CPT: pharmacometrics & systems pharmacology

Published: December 07, 2023

Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study.

Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 03, 2023

Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data.

Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 20, 2023

What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?

What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?

Journal: Expert opinion on drug metabolism & toxicology

Published: June 09, 2023

Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates.

Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates.

Journal: European journal of drug metabolism and pharmacokinetics

Published: May 14, 2023

Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers.

Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers.

Journal: Open forum infectious diseases

Published: March 28, 2023

Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen.

Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen.

Journal: British journal of clinical pharmacology

Published: January 19, 2023

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals.

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals.

Journal: Clinical pharmacokinetics

Published: November 28, 2022

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study.

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: August 24, 2022

Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models.

Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models.

Journal: Clinical pharmacokinetics

Published: April 28, 2022

Showing 1-12 of 13

Last Updated: 09/26/2026